Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial  Boni E. Elewski, MD, Martin.

Published by然纣 慕 Modified over 5 years ago

Similar presentations

Presentation on theme: "Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial  Boni E. Elewski, MD, Martin."— Presentation transcript:

1 Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial  Boni E. Elewski, MD, Martin M. Okun, MD, Kim Papp, MD, Christopher S. Baker, MBBS, Jeffrey J. Crowley, MD, Gérard Guillet, MD, Murali Sundaram, PhD, Yves Poulin, MD, Yihua Gu, MS, Ziqian Geng, PhD, David A. Williams, MD, Phoebe A. Rich, MD  Journal of the American Academy of Dermatology  Volume 78, Issue 1, Pages e1 (January 2018) DOI: /j.jaad Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Study design. ∗Initial dose of adalimumab was 80 mg, followed by 40 mg every other week starting 1 week later. †Starting at week 16, if the psoriasis-affected body surface area increased 25% or more over baseline, patients were rolled over to the open-label extension period. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Patient disposition. The 26-week open-label extension period (period B) is not reported. For those patients who discontinued study participation for more than 1 reason, only the primary reason is listed. BSA, Body surface area; OLE, open-label extension; Ps, psoriasis Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Primary efficacy end point. Multiple imputation. Statistically significant at ***P < .001. ADA, Adalimumab; mNAPSI, modified Nail Psoriasis Severity Index; PBO, placebo. *Primary end point was at week 26. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Ranked secondary end points. A, Mean percent improvement in total Nail Psoriasis Severity Index (NAPSI). B, Achievement of total fingernail modified Nail Psoriasis Severity Index (mNAPSI) of 0. C, Mean improvement in nail (psoriasis) Ps pain Numeric Rating Scale (NRS). D, Mean improvement in Nail Psoriasis Physical Functioning Severity (NPPFS). E, Achievement of at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index among patients with baseline scalp score of 6 or higher (B-SNIPI50). F, Achievement of Physician's Global Assessment of Fingernail Psoriasis (PGA-F) score of 0 or 1 with 2 or more grades of improvement from baseline. *Ranked secondary end points were at week 26; total nail end points were collected only at weeks 16 and 26. Multiple imputation. Statistically significant at ***P < .001 and **P < .01. ADA, Adalimumab; PBO, placebo. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Improvement over time in target fingernail. A, modified Nail Psoriasis Severity Index (mNAPSI75) response rate of at least 75% relative to baseline in target fingernail. B, Mean percent improvement in target fingernail Nail Psoriasis Severity Index (NAPSI). Multiple imputation. Statistically significant at ***P < .001. ADA, Adalimumab; PBO, placebo. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial  Boni E. Elewski, MD, Martin."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Cutaneous myiasis associated with scalp psoriasis

Cutaneous myiasis associated with scalp psoriasis
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Similar presentations

Ads by Google